Discover the latest insights from the COMPARE study, which unveils the effectiveness of third-generation antiseizure medications in the real world, potentially revolutionizing the approach to epilepsy treatment.
– by Klaus
Note that Klaus is a Santa-like GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
A real-world comparison among third-generation antiseizure medications: results from the COMPARE study.
Roberti et al., Epilepsia 2023
DOI: 10.1111/epi.17843
Ho-ho-ho! Gather ’round, my curious elves, for a tale of modern medicine in the land of epilepsy treatment. In a study as bustling and busy as my workshop on Christmas Eve, a group of diligent doctors from 22 Italian neurology centers embarked on a mission to compare the effectiveness of four shiny, third-generation antiseizure medications (ASMs) – brivaracetam (BRV), eslicarbazepine acetate (ESL), lacosamide (LCM), and perampanel (PER).
These medical Santas, with their lists of adult patients who had been good candidates for add-on treatment between January 2018 and October 2021, checked them not twice, but thoroughly, to see how well these ASMs worked. They used a magical measure called the retention rate, which is like seeing how long a toy lasts in the hands of an excited child, and they drew their conclusions using Kaplan-Meier curves, which are as curvy as candy canes, and the best fitting survival model, as snug as a stocking on a mantelpiece.
Now, my elves, let’s peek into the sack of findings. It turns out that compared to LCM, the other ASMs had a higher risk of patients saying “no thank you” and discontinuing treatment, especially with BRV in those who hadn’t tried levetiracetam (LEV) and with PER. Women, bless their hearts, were more likely to stop taking ESL, and PER was a bit of a challenge for patients whose epilepsy cause was as mysterious as the exact location of my workshop.
But it wasn’t all lumps of coal. BRV showed a twinkle of promise, especially in women who were LEV-naïve, and PER and BRV in LEV-naïve patients had a higher chance of adverse events than LCM, which is as important to know as the proper way to wrap a present.
In the end, my dear elves, this study is like a guidebook for clinicians to tailor treatments as carefully as we tailor our toys for each child. It’s a reminder that in the world of epilepsy treatment, one size does not fit all, and the best gift we can give is the gift of personalized care. Now, let’s get back to our toy-making, and let these fine doctors get back to their important work! 🎅🎄